ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ETNB 89bio Inc

11.64
0.33 (2.92%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 840,223
Bid Price 11.13
Ask Price 12.12
News -
Day High 11.69

Low
6.575

52 Week Range

High
22.93

Day Low 11.01
Company Name Stock Ticker Symbol Market Type
89bio Inc ETNB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.33 2.92% 11.64 20:00:00
Open Price Low Price High Price Close Price Prev Close
11.52 11.01 11.69 11.64 11.31
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,385 840,223 $ 11.40 $ 9,578,427 - 6.575 - 22.93
Last Trade Time Type Quantity Stock Price Currency
18:36:56 7 $ 11.70 USD

89bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.09B 93.50M - 0 -142.19M -1.52 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

89bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ETNB Message Board. Create One! See More Posts on ETNB Message Board See More Message Board Posts

Historical ETNB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.4611.8911.0011.36794,6050.181.57%
1 Month11.9016.6311.0012.691,676,065-0.26-2.18%
3 Months11.0716.637.4711.181,376,3680.575.15%
6 Months15.1016.636.57510.031,578,115-3.46-22.91%
1 Year16.3322.936.57513.281,430,705-4.69-28.72%
3 Years25.0628.282.0011.87872,013-13.42-53.55%
5 Years20.0047.25322.0012.74632,082-8.36-41.80%

89bio Description

89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Your Recent History

Delayed Upgrade Clock